Elvir Becirovic is the Head of Novel Gene Therapy Technologies Group at Ludwig-Maximillians-Universität, Munich. He has more than thirteen years of experience in (molecular) genetics, protein biochemistry, gene functions & therapy. Elvir has a strong track record in functional characterization of retinal disorders in combination with novel applications utilizing AAV vectors. He is principal investigator and co-principal investigator on DFG grants for retinal gene therapy and development of novel AAV vector-based treatment strategies for therapy of retinal diseases. He has authored over 40 publications.
Elvir has a Ph.D. in Pharmacology from LMU Munich, where he also completed his postdoctoral fellowship.